M
Marta Halasa
Researcher at Medical University of Lublin
Publications - 17
Citations - 293
Marta Halasa is an academic researcher from Medical University of Lublin. The author has contributed to research in topics: Vorinostat & Cancer cell. The author has an hindex of 7, co-authored 16 publications receiving 138 citations.
Papers
More filters
Journal ArticleDOI
Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells
Anna Wawruszak,Joanna Kałafut,Estera Okon,Jakub Czapinski,Jakub Czapinski,Marta Halasa,Alicja Przybyszewska,Paulina Miziak,Karolina Okła,Adolfo Rivero-Müller,Adolfo Rivero-Müller,Andrzej Stepulak +11 more
TL;DR: The aim of this review is to compile and discuss the most recent findings on the effect of HDIs on the epithelial-mesenchymal transition (EMT) process in human cancers.
Journal ArticleDOI
H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy
Marta Halasa,Anna Wawruszak,Alicja Przybyszewska,Anna Jaruga,Anna Jaruga,Małgorzata Guz,Joanna Kałafut,Andrzej Stepulak,Marek Cybulski +8 more
TL;DR: The level of H3K18Ac in different cancer cell lines is summarized and its association with patients’ outcomes is analyzed, including overall survival (OS), progression-free survival (PFS), and disease- free survival (DFS).
Journal ArticleDOI
Advances in Chemistry and Bioactivity of Magnoflorine and Magnoflorine-Containing Extracts
TL;DR: The review collects together some recent information on the identity and pharmacological properties of magnoflorine, a quaternary aporphine alkaloid that is widely distributed within the representatives of several botanical families like Berberidaceae, Magnoliaceae, Papaveraceae, or Menispermaceae.
Journal ArticleDOI
Valproic Acid and Breast Cancer: State of the Art in 2021.
TL;DR: In this article, a review of in vitro and in vivo experimental data on VPA, applied individually or in combination with other anti-cancer agents, in the treatment of different histological subtypes of breast cancer is presented.
Journal ArticleDOI
Vorinostat (SAHA) and Breast Cancer: An Overview.
TL;DR: Vorinostat (SAHA) is the first histone deacetylase inhibitor (HDI) approved for the treatment of cutaneous T-cell lymphoma in 2006.